Molecular Genotyping of Follicular Variant of Papillary Thyroid Carcinoma Correlates with Diagnostic Category of Fine-Needle Aspiration Cytology: Values of *RAS* Mutation Testing

Sang Ryung Lee,¹ Chan Kwon Jung,¹ Tae Eun Kim,¹ Ja Seong Bae,²
So Lyung Jung,³ Yeong Jin Choi,¹ and Chang Suk Kang¹

Background: The follicular variant of papillary thyroid carcinoma (FVPTC) presents distinct histologic subtypes and molecular genotyping. The preoperative diagnosis of FVPTC through fine-needle aspiration cytology (FNAC) is challenging.

Methods: We reviewed 59 archival thyroid FNAC specimens of surgically confirmed FVPTC according to histologic subtype: encapsulated FVPTC ($n=30$) and infiltrative FVPTC ($n=29$). Galectin-3 immunostaining and molecular analyses for *BRAF* and three *RAS* genes (*NRAS*, *HRAS*, and *KRAS*) were performed.

Results: FNAC diagnoses of FVPTC included benign (5%), atypia of undetermined significance (19%), follicular neoplasm/suspicious for follicular neoplasm (14%), suspicious for PTC (29%), and PTC (34%). Galectin-3 immunostaining was positive in 50% of FNAC specimens. A *BRAF* mutation was found only in 14 (24%) tumors with the FNAC diagnosis of PTC or suspicious for PTC: 13 cases with the usual c.1799T>A (p.V600E) mutation and 1 case with a 3 base-pair deletion (c.1799_1801delTGA), resulting in a deletion of lysine at codon 601 and a deletion c.1799_1801delTGA that results in a valine-to-glutamate substitution at codon 600 (p.V600_K601>E) while preserving the reading frame. A *BRAF* K601E mutation was not found. *RAS* mutations were observed in 18 (33%) tumors (*NRAS*, 22%; *HRAS*, 6%; *KRAS*, 6%). Mutations of the three *RAS* genes were detected in codon 61 but not in codons 12 and 13. There was a decreasing trend of *RAS* mutation rates associated with an increasing risk of malignancy in the FNAC diagnostic categories. The triage efficacy of FNAC to make a recommendation for surgery was 73% for encapsulated tumors and 79% for infiltrative tumors. Addition of galectin-3 or the *BRAF* test to FNAC showed no significant improvement in the triage efficacy. However, *RAS* mutations significantly improved the triage efficacy of FNAC. There was no significant difference in the triage efficacy of FNAC, galectin-3 expression, and the prevalence of somatic mutations between encapsulated and infiltrative tumors.

Conclusion: Thyroid FNAC has a low sensitivity for the detection of FVPTC regardless of histologic subtype. Encapsulated FVPTC and infiltrative FVPTC have similar molecular profiles and rates of galectin-3 expression. *RAS* mutational analysis is more useful than *BRAF* testing to improve the triage efficacy of FNAC for FVPTC.

Introduction

THE FOLLICULAR VARIANT of papillary thyroid carcinoma (FVPTC) is a common variant comprising 15–20% of all papillary thyroid carcinoma (PTC) (1,2). The diagnosis of FVPTC is based on its histologic features comprising characteristic nuclear features of PTC and an exclusive or predominant (>50%) follicular growth pattern without well-formed papillae (3,4). FVPTC is divided into two subtypes, encapsulated and infiltrative, by the presence or absence of encapsu-

lation (4–6). Encapsulated FVPTC is totally encapsulated by a fibrous tissue and may show tumor capsular or vascular invasion (4–6). The histopathologic diagnosis of infiltrative FVPTC usually poses no problem because the tumor infiltrates the surrounding thyroid parenchyma without a well-defined capsule but with the presence of most of the characteristic nuclear features of PTC. However, the diagnosis of the encapsulated subtype may be particularly difficult because the diagnostic nuclear features of PTC may be moderately developed and intermixed with cells lacking the

Departments of ¹Hospital Pathology, ²Surgery, and ³Radiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

diagnostic nuclear features in encapsulated FVPTC. Overall, the clinical behavior of infiltrative FVPTC is similar to that of classic PTC with a high rate of lymph node metastasis, whereas encapsulated FVPTC has a behavior much closer to that of follicular adenoma and follicular carcinoma with a low rate of lymph node metastasis (7). In addition to the encapsulated and infiltrative subtypes of FVPTC, a rare aggressive diffuse follicular variant was originally described by Sobrinho-Simões *et al.* in 1990 (8). The diffuse FVPTC occurs primarily in young females and is characterized by extensive, multifocal involvement of one or both lobes of the thyroid gland (6,9,10).

Fine-needle aspiration cytology (FNAC) is the most reliable and commonly used diagnostic method for thyroid nodules. The Bethesda System for Reporting Thyroid Cytopathology was introduced to reduce ambiguous and implicit thyroid FNAC interpretations through the use of a standardized terminology and general diagnostic categories (11,12). Each diagnostic category has an implied risk of malignancy as well as a recommended clinical management.

The cytopathologic diagnosis of FVPTC is challenging in FNAC because nuclear changes are often subtle and the characteristic nuclear features of PTC can be partially and focally displayed (13–16). The diagnostic sensitivity of FNAC for FVPTC ranges from 9% to 75%, which is very low compared with that of FNAC for classic PTC. FVPTC is a major cause of the cases with false-negative results in FNAC (13–17). Therefore, the diagnosis of FVPTC by cytomorphology alone has limitations and thus requires additional methods such as immunostaining and molecular testing to facilitate the diagnosis of FVPTC.

Galectin-3, a β -galactoside-binding lectin, has been used to aid the differential diagnosis between thyroid cancer and benign thyroid lesions from FNAC samples and surgical tissue specimens (18). Positive galectin-3 immunostaining is observed in almost all classic PTCs, whereas in FVPTC, the positive rate is lower and more focal, and of moderate to weak intensity (18). A difference may exist in galectin-3 expression for FVPTC between postsurgical tissues and clinical FNAC samples.

FVPTCs frequently harbor RAS mutations and have a relatively low rate of BRAF mutations compared to classic PTC (19–21). However, there is controversy about the BRAF and RAS mutational patterns of FVPTC according to its histologic subtypes. Rivera *et al.* (5) reported that encapsulated FVPTC had a high rate of RAS and an absence of BRAF mutations, while the infiltrative variant showed a molecular profile with a high prevalence of BRAF and a low frequency of RAS mutations. Infiltrative FVPTC had a BRAF and RAS mutational pattern in between follicular neoplasms and classic PTC, whereas the molecular profile of encapsulated FVPTC was similar to follicular neoplasms. However, Gupta *et al.* (6) found that the two subtypes had similar clinical behaviors and mutation rates for BRAF and RAS.

We therefore analyzed the efficacy of FNAC to make a recommendation for surgery based on the Bethesda System in patients with FVPTC and investigated the molecular profiles of FVPTC according to its histologic subtypes, which may play a role as an adjunctive diagnostic tool along with traditional FNAC.

Materials and Methods

This study was approved by the Institutional Review Board of the Catholic University of Korea Seoul St. Mary's Hospital,

and written informed consent was obtained from all subjects or their legal guardians.

Case collection

A total of 59 consecutive patients with FVPTC were enrolled in this study and underwent surgery at Seoul St. Mary's Hospital between January 2011 and April 2012. All histological slides were reviewed independently by three experienced pathologists (S.R.L., C.K.J., and Y.J.C.) with a special interest in thyroid pathology who were familiar with FVPTC histology, and consensus diagnoses were made following the World Health Organization classification (3). All patients enrolled in this study underwent ultrasound-guided FNAC prior to surgery. All FNAC cases were classified into six-tiered diagnostic categories using the Bethesda System for Reporting Thyroid Cytopathology. FVPTC was defined as a papillary carcinoma predominantly composed of follicles (>50% of the tumor) and a complete lack of well-formed papillae. All tumors were classified into encapsulated and infiltrative subtypes based on histologic growth patterns only, irrespective of tumor size. We did not consider whether the tumor was a microcarcinoma, which is defined as a malignant tumor of ≤ 1 cm in diameter. The rare diffuse follicular variant was not included in this study.

Triage efficacy of FNAC to make a recommendation for surgery was defined as FNAC classification as follicular neoplasm/suspicious for a follicular neoplasm, suspicious for malignancy, or PTC that triggers surgical management. Diagnostic accuracy was defined as FNAC classification as suspicious for malignancy or PTC (17).

Galectin-3 immunohistochemical staining

Immunohistochemical staining was performed on both FNAC-derived cell blocks and corresponding surgical specimens as previously described (22). A mouse monoclonal antibody against galectin-3 (1:800; Novocastra Lab., Newcastle upon Tyne, United Kingdom) was applied for 30 minutes at room temperature. Immunoreaction was detected using the EnVision Plus System (Dako, Carpinteria, CA) and by counterstaining with hematoxylin. Galectin-3 expression was considered positive on both tissue and cell block sections if >5% of tumor cells displayed cytoplasmic and nuclear immunostaining.

Mutational analysis of BRAF and RAS genes

Genomic DNA was isolated from two 10- μ m-thick formalin-fixed, paraffin-embedded tissue sections containing a representative portion of each archival tissue block using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). Tumor areas were manually microdissected from the tissue sections. We performed mutational analysis of exon 15 of the BRAF gene and exons 2 and 3 of the NRAS, HRAS, and KRAS genes using PCR amplification and DNA sequencing, as described earlier (23–25).

Statistical analysis

Continuous parametric data with a normal distribution were compared using the Student's *t*-test. The nonparametric Mann-Whitney *U*-test was used to analyze continuous data with a skewed distribution. Categorical data were compared using the chi-squared test. The Fisher's exact test was used when more than 20% of cells had less than 5 expected

TABLE 1. DISTRIBUTION OF FINE-NEEDLE ASPIRATION CYTOLOGY DIAGNOSES ACCORDING TO THE HISTOLOGIC SUBTYPES OF FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA

Diagnostic category	Encapsulated	Infiltrative	Total
Nondiagnostic	0	0	0
Benign	1 (3%)	2 (7%)	3 (5%)
Atypia of undetermined significance	7 (23%)	4 (14%)	11 (19%)
Follicular neoplasm/suspicious for a follicular neoplasm	3 (10%)	5 (17%)	8 (14%)
Suspicious for papillary carcinoma	8 (27%)	9 (31%)	17 (29%)
Papillary carcinoma	11 (37%)	9 (31%)	20 (34%)
Total	30 (100%)	29 (100%)	59 (100%)

frequencies for categorical data with a lower number of samples. The linear-by-linear association test was used to analyze the change of molecular genotyping as progressing in severity from benign to malignant FNAC diagnostic categories (p_{trend}). All analyses were performed with the use of SPSS version 16.0 (SPSS Inc., Chicago, IL). Two-sided p -values of ≤ 0.05 were considered statistically significant.

Results

Patient characteristics

The study population comprised 59 patients (45 women and 14 men). The age of the patients at the time of surgery ranged from 20 to 79 years (mean 48.4 years). According to the histologic subtypes of FVPTC, 30 of 59 cases were encapsulated variants and 29 were infiltrative variants. There was no significant difference in the mean age between patients (47.4 years) with encapsulated FVPTC and those (49.3 years) with infiltrative FVPTC ($p=0.546$). The median size of encapsulated and infiltrative tumors was 0.9 and 0.6 cm, respectively ($p=0.132$). Out of a total of 59 patients, 32 had two or more tumor foci. The largest tumor foci from five patients were classic PTC. Therefore, we excluded the 5 cases and further analyzed the clinicopathologic features of 54 patients according to the histologic subtypes of the FVPTC. There were no significant difference in age, sex, pT stage, extrathyroid extension, multifocality, or lymph node metastasis between patients with encapsulated tumors and those with infiltrative tumors (Supplementary Table S1; Supplementary Data are available online at www.liebertpub.com/thy).

Fine-needle aspiration cytology

FNAC diagnoses of FVPTC included benign (5%), atypia of undetermined significance (19%), follicular neoplasm/suspi-

cious for a follicular neoplasm (14%), suspicious for PTC (29%), and PTC (34%). There was no significant difference in the distribution of FNAC diagnostic categories between encapsulated and infiltrative FVPTC (Table 1).

Galectin-3 immunostaining

Out of a total of 59 FNAC specimens, 38 cases had residual follicular cells on cell blocks available for galectin-3 immunostaining. Positive staining for galectin-3 was observed in 19 (50%) FNAC specimens, including 8 (42%) encapsulated and 11 (58%) infiltrative subtypes. Of 58 tissue specimens, 44 cases (76%) containing 19 (66%) encapsulated and 25 (86%) infiltrative subtypes expressed galectin-3 protein. The overall positive rate of galectin-3 expression was higher in tissue specimens (76%) than in cell blocks (50%). There was no significant difference between the positive rates of galectin-3 expression in encapsulated and infiltrative subtypes irrespective of specimen type (Table 2).

Molecular analysis

The molecular alterations found in the analyzed FVPTC are summarized in Table 3. A *BRAF* mutation was detected in 14 (24%) of 58 tumors, including 7 (23%) encapsulated and 7 (25%) infiltrative tumors. The total mutation rate of the three *RAS* genes was 33% (18/54). Positive cases consisted of *NRAS*, *HRAS*, and *KRAS* mutations in 12 (22%), 3 (6%), and 3 (6%) cases, respectively. *RAS* mutations were detected in codon 61 of the three *RAS* genes, but not in codons 12 and 13. There was no statistically significant difference in the prevalence of somatic mutations between encapsulated and infiltrative tumors (Table 4). Among FVPTC, *RAS*-mutated tumors were significantly larger than non-*RAS*-mutated tumors (mean 1.3 cm vs. 0.9 cm, $p=0.013$). However, there were no significant differences in age, sex, pT stage, extrathyroid extension, multifocality, or lymph node metastasis between the *RAS* mutation status and the clinicopathologic features of FVPTC (Supplementary Table S2).

Comparison of molecular profiles and FNAC results

We compared the results of molecular profiles with the diagnostic results of FNAC. A *BRAF* mutation was found in 45% and 29% of cases that were diagnosed as PTC and suspicious for PTC by FNAC, respectively. However, all cases that were cytopathologically diagnosed as benign, atypia of undetermined significance, or follicular neoplasm/suspicious for a follicular neoplasm showed negative results for *BRAF* mutations. There was a decreasing trend of *RAS* mutation rates associated with increasing risk of malignancy in the FNAC diagnostic categories ($p_{\text{trend}}=0.002$), while there was an increasing trend of *BRAF* mutation rate among these categories ($p_{\text{trend}}=0.001$; Fig. 1).

TABLE 2. GALECTIN-3 IMMUNOSTAINING ON FINE-NEEDLE ASPIRATION CYTOLOGY AND SURGICAL SPECIMENS ACCORDING TO THE HISTOLOGIC SUBTYPES OF FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA

Specimen type	Galectin-3	Encapsulated	Infiltrative	p	Total
Cell block	Negative	11/19 (58%)	8/19 (42%)	0.330	19/38 (50%)
	Positive	8/19 (42%)	11/19 (58%)		19/38 (50%)
Surgical specimen	Negative	10/29 (35%)	4/29 (14%)	0.066	14/58 (24%)
	Positive	19/29 (66%)	25/29 (86%)		44/58 (76%)

TABLE 3. FREQUENCY OF MUTATIONS IN FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FOR THE *BRAF* AND *RAS* GENES

Nucleotide change	Amino acid change	No. of mutated cases
<i>BRAF</i> codon 600–601		
c.1799T>A	p.V600E	13/58 (22%)
c.1799_1801delTGA	p.V600_K601>E ^a	1/58 (2%)
<i>NRAS</i> codon 12–13		
none		
<i>NRAS</i> codon 61		
c.181C>A	p.Q61K	3/54 (6%)
c.182A>G	p.Q61R	9/54 (17%)
<i>HRAS</i> codon 12–13		
none		
<i>HRAS</i> codon 61		
c.182A>G	p.Q61R	3/54 (6%)
<i>KRAS</i> codon 12–13		
none		
<i>KRAS</i> codon 61		
c.182A>G	p.G61R	2/54 (4%)
c.180_181TC>AA	p.G61K	1/54 (2%)

^aThis rare deletion mutation in the *BRAF* gene (c.1799_1801 delTGA) converts codons 600 GTG (valine) and 601 AAA (lysine) to a new single codon GAA (glutamic acid) (p.V600_K601>E) while preserving the reading frame of the coding region of the gene.

FNAC triage efficacy and diagnostic accuracy

The FNAC triage efficacy for triggering surgery was 76%, and the diagnostic accuracy of FNAC was 63%. There was no significant difference in these diagnostic values of FNAC according to the histologic subtypes of FVPTC. Although molecular testing was done using surgical specimens instead of FNAC specimens, we tried to analyze whether molecular testing can improve the triage efficacy of FNAC (Table 5). Galectin-3 immunostaining and the *BRAF* mutation test did not improve the triage efficacy or diagnostic accuracy. However, *RAS* mutation testing significantly improved the triage efficacy of FNAC from 76% to 91% ($p < 0.001$).

Discussion

Unlike classic PTC, FVPTC shows wide variation in the distribution of characteristic cytologic features of PTC in FNAC specimens and is therefore more challenging to diagnose (17,26,27). The rate of malignant category of FNAC diagnoses in patients with FVPTC ranges from 9% to 38% (13,14,17,26,27). In our study, 20 (34%) of 59 FVPTCs were classified as malignant on the FNAC specimens.

TABLE 4. MOLECULAR GENOTYPE ACCORDING TO THE HISTOLOGIC SUBTYPES OF FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA

Genotype	Encapsulated	Infiltrative	p	Total
<i>BRAF</i> mutation	7/30 (23%)	7/28 (25%)	0.882	14/58 (24%)
<i>RAS</i> mutation	11/28 (39%)	7/26 (27%)	0.336	18/54 (33%)
Somatic mutation	18/28 (64%)	14/26 (54%)	0.435	32/54 (59%)

FIG. 1. Molecular genotype according to the diagnostic categories of fine-needle aspiration cytology. A p -value for trend was analyzed by the linear-by-linear association test ($p_{\text{trend}} < 0.001$). PTC, papillary thyroid carcinoma. Color images available online at www.liebertpub.com/thy

The *BRAF* V600E mutation constitutes the vast majority of all *BRAF* alterations detected in thyroid tumors and is found in about 45% of PTC, with a range of 29–83% (28). Another *BRAF* mutation, K601E, has been reported in up to 9% of FVPTCs (29). The *BRAF* V600E mutation is present in about 10–20% of FVPTC (27,28,30). We have previously reported that the *BRAF* V600E mutation was found in 839 (81%) of 1041 Korean patients with PTC (23). In the present study, the prevalence of this mutation was 24% for FVPTC and the *BRAF* K601E mutation was not found. In a 54-year-old man with a 3.3 cm encapsulated oncocytic FVPTC, we found a deletion of 3 bp, TGA (coding nucleotide 1799–1801), in exon 15 of the *BRAF* gene. The in-frame deletion of TGA (c.1799_1801delTGA) results in a deletion of lysine at codon 601 and a valine-to-glutamate substitution at codon 600 in the resultant *BRAF* protein (p.V600_K601>E) while preserving the reading frame of the coding region of the gene.

Our study revealed a distinct stratification in the molecular profile of FVPTC according to the severity of the preceding cytopathologic diagnosis in the Bethesda System. FVPTCs with FNAC diagnoses of “benign,” “atypia of undetermined significance,” or “follicular neoplasm/suspicious for a follicular neoplasm” harbored *RAS* mutations, but no *BRAF* mutations. A decreasing trend of *RAS* mutation rate progressing

TABLE 5. TRIAGE EFFICACY FOR TRIGGERING SURGERY IN FINE-NEEDLE ASPIRATION CYTOLOGY

	Encapsulated	Infiltrative	Total
FNAC alone	22/30 (73%)	23/29 (79%)	45/59 (76%)
FNAC & galectin-3	1/11 (9%)	27/27 (100%)	28/38 (74%)
FNAC & <i>BRAF</i> mutation	22/30 (73%)	23/28 (82%)	45/58 (78%)
FNAC & <i>RAS</i> mutation	26/28 (93%)	23/26 (89%)	49/54 (91%)
FNAC & somatic mutation	27/29 (93%)	25/28 (89%)	52/57 (91%)

FNAC, fine-needle aspiration cytology; triage efficacy, defined as classification of an FNAC as papillary thyroid carcinoma, suspicious for malignancy, or follicular neoplasm.

in severity from benign to malignant FNAC diagnostic categories was detected. One possible reason for the change in the molecular profile according to the cytologic diagnosis is the morphologic heterogeneity of FVPTC. Therefore, the diagnosis of FVPTC may not be so clear by microcopy, especially in the encapsulated subtype. High interobserver variability has been reported for this tumor (31,32). When there was a complete agreement about the diagnosis of FVPTC among the pathologists, the *BRAF* mutation rate was 25%, whereas no FVPTCs with a low consensus of diagnosis harbored the mutation (33). In the present study, there were no significant differences in the distribution of FNAC diagnoses, galectin-3 positivity, and molecular profiles between encapsulated FVPTCs and infiltrative FVPTCs. FVPTCs with the lesser degrees of cytologic features of PTC were diagnosed as "benign," "atypia of undetermined significance," or "follicular neoplasm/suspicious for a follicular neoplasm" and had a high rate of *RAS* mutations and no *BRAF* mutations, whereas FVPTCs with readily recognizable cytologic features of PTC were easily diagnosed as malignant/suspicious for malignancy and harbored a high rate of *BRAF* mutations and a low rate of *RAS* mutations. Therefore, in clinical practice, the *RAS* mutation test may be more useful as an ancillary test rather than the *BRAF* test or galectin-3 immunostaining in the diagnosis of FVPTC using FNAC specimens.

Different specimen types of FNAC and surgical specimens may induce different results of immunostaining and molecular testing in the sample nodule. In our study, cell blocks were available in 38/59 FNAC specimens. We noted galectin-3 positivity of 50% (19/38) in FNAC specimens and 76% (44/58) in surgical tissue. Before this study, we examined the preliminary concordance of molecular tests between FNAC and surgical specimens using 20 cell blocks containing sufficient amounts of follicular cells for molecular testing and corresponding resection specimens. All 20 cases had 100% concordance of molecular analyses for the *BRAF* and *RAS* genes between the two types of specimens.

RAS mutations are not specific for malignancy but may occur in benign thyroid lesions. They are found in 40–50% of conventional follicular carcinomas, about 40% of FVPTCs, and about 30% of benign follicular adenomas (34). Despite the lack of specificity for malignancy, it has been reported that *RAS* mutation testing improves the diagnostic accuracy of FNAC (24). In a large prospective study, a *RAS*-positive nodule in an FNAC sample had an 87.5% probability of malignancy (24). Furthermore, *RAS*-positive follicular adenoma is likely to progress to follicular carcinoma and FVPTC (24). For these reasons, surgical resection may be justified in patients with *RAS*-positive adenomas for the prevention of their disease progression. In the present study, the overall *RAS* mutation rate of FVPTCs was 33% (18/54). Specifically, the mutation rates were 67%, 56%, and 63% in FNACs diagnosed as "benign," "atypia of undetermined significance," or "follicular neoplasm/suspicious for a follicular neoplasm," respectively. Therefore, our study provides evidence that *RAS* mutation testing may be diagnostically useful to decrease the false-negative rate. However, routine molecular testing is not recommended for all patients with benign cytologic diagnosis.

Out of the three *RAS* genes (*NRAS*, *HRAS*, and *KRAS*) found in thyroid cancers, the most frequently affected hot spots are *NRAS* codon 61 and *HRAS* codon 61. Much lower mutation rates have been found in *KRAS* codons 12 and 13

(34,35). In the present study, the *NRAS* codon 61 mutation was most common. Interestingly, *KRAS* mutations only involved codon 61, but not codons 12 and 13. These data are similar to those reported in a recent molecular study in which the *KRAS* codon 61 mutation was found in 1 of 22 encapsulated FVPTCs (6). We therefore suggest that *KRAS* mutation testing for thyroid cancer should include codon 61 analysis as well as codons 12 and 13.

We observed that FVPTCs with *RAS* mutations are larger than FVPTCs with wild-type *RAS*. This finding is in accordance with the data on record (5,19). In follicular thyroid carcinomas, the presence of a *RAS* mutation is also correlated with a large tumor size (34). The *NRAS* codon 61 mutation is associated with distant metastasis, and *RAS* mutations are associated with poor overall patient survival (36). The *NRAS* codon 61 mutation has also been reported in FVPTCs with distant metastasis (5). Gupta *et al.* (6) observed that encapsulated FVPTC had a molecular profile and clinical behavior similar to those of infiltrative FVPTC. In the present study, there were no differences in the mutation rates of *RAS* and *BRAF* between encapsulated and infiltrative FVPTC. Tumors with *RAS* mutations showed no significant differences in clinicopathologic features compared to the *RAS* wild-type group. However, limitations of the present study include a small sample size, retrospective design, and enrollment of patients with tumors of less than 1 cm in size. Further studies are needed to elucidate the role of *RAS* mutations in FVPTC and to clarify the differences between the clinicopathologic characteristics and prognostic factors in patients with encapsulated and infiltrative FVPTC.

Out of a total of 59 patients, 3 had a benign cytologic diagnosis; however, they underwent surgical excision because of cytologic diagnoses of PTC or follicular neoplasm in the opposite lobe, or another fast growing nodule with suspicious sonographic findings in the same lobe (Supplementary Table S3).

In conclusion, we found that thyroid FNAC had a low sensitivity for detecting FVPTC regardless of histologic subtype. Encapsulated and infiltrative FVPTCs had similar molecular and galectin-3 expression profiles. *RAS* mutational analysis is a useful ancillary tool to improve the triage efficacy of FNAC for FVPTC, but *BRAF* testing does not improve the preoperative diagnostic accuracy of FNAC for FVPTC.

Acknowledgments

The authors wish to acknowledge the financial support of the Catholic Medical Center Research Foundation made in the program year of 2012. This research was partially supported by a research grant 2011 from Korean Thyroid Association.

Author Disclosure Statement

The authors declare that no competing financial interests exist.

References

1. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J 1985 Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. *Cancer* 55:805–828.
2. Lam AK, Lo CY, Lam KS 2005 Papillary carcinoma of thyroid: a 30-yr clinicopathological review of the histological variants. *Endocr Pathol* 16:323–330.

3. LiVolsi VA, Albores-Saavedra J, Asa SL, Baloch ZW, Sobrinho-Simões M, Wenig B, DeLellis RA, Cady B, Mazzaferri EL, Hay I, Fagin JA, Weber AL, Caruso P, Voutilainen PE, Franssila KO, Williams ED, Schneider AB, Nikiforov YE, Rabes HM, Akslen L, Ezzat S, Santoro M, Eng C, Harach HR 2004 Papillary carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs, Vol. I. ARC Press, Lyon, France, pp 57–66.
4. Nikiforov YE, Ohori NP 2012 Papillary carcinoma. In: Nikiforov YE, Biddinger PW, Thompson LDR (eds) Diagnostic Pathology and Molecular Genetics of the Thyroid. 2nd ed. Lippincott Williams & Wilkins, Philadelphia, PA, pp 183–246.
5. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA 2010 Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. *Mod Pathol* **23**:1191–1200.
6. Gupta S, Ajise O, Dultz L, Wang B, Nonaka D, Ogilvie J, Heller KS, Patel KN 2012 Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities. *Arch Otolaryngol Head Neck Surg* **138**:227–233.
7. Ghossein R 2010 Encapsulated malignant follicular cell-derived thyroid tumors. *Endocr Pathol* **21**:212–218.
8. Sobrinho-Simões M, Soares J, Carneiro F, Limbert E 1990 Diffuse follicular variant of papillary carcinoma of the thyroid: report of eight cases of a distinct aggressive type of thyroid tumor. *Surg Pathol* **3**:189–203.
9. Ivanova R, Soares P, Castro P, Sobrinho-Simoes M 2002 Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. *Virchows Archiv* **440**:418–424.
10. Mizukami Y, Nonomura A, Michigishi T, Ohmura K, Noguchi M, Ishizaki T 1995 Diffuse follicular variant of papillary carcinoma of the thyroid. *Histopathology* **27**:575–577.
11. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ 2008 Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. *Diagn Cytopathol* **36**:425–437.
12. Lee K, Jung CK, Lee KY, Bae JS, Lim DJ, Jung SL 2010 Application of Bethesda System for reporting thyroid aspiration cytology. *Korean J Pathol* **44**:521–527.
13. Goodell WM, Saboorian MH, Ashfaq R 1998 Fine-needle aspiration diagnosis of the follicular variant of papillary carcinoma. *Cancer* **84**:349–354.
14. Kesmodel SB, Terhune KP, Canter RJ, Mandel SJ, LiVolsi VA, Baloch ZW, Fraker DL 2003 The diagnostic dilemma of follicular variant of papillary thyroid carcinoma. *Surgery* **134**:1005–1012; discussion 1012.
15. Lin HS, Komisar A, Opher E, Blaugrund SM 2000 Follicular variant of papillary carcinoma: the diagnostic limitations of preoperative fine-needle aspiration and intraoperative frozen section evaluation. *Laryngoscope* **110**:1431–1436.
16. Tielens ET, Sherman SI, Hruban RH, Ladenson PW 1994 Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. *Cancer* **73**:424–431.
17. Kurian EM, Dawlett M, Wang J, Gong Y, Guo M 2012 The triage efficacy of fine needle aspiration biopsy for follicular variant of papillary thyroid carcinoma using the Bethesda reporting guidelines. *Diagn Cytopathol* **40**(Suppl 1):E69–E73.
18. Chiu CG, Strugnelli SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM 2010 Diagnostic utility of galectin-3 in thyroid cancer. *Am J Pathol* **176**:2067–2081.
19. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P, Sobrinho-Simoes M 2006 PAX8-PPARGgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. *J Clin Endocrinol Metab* **91**:213–220.
20. Di Cristofaro J, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D, De Micco C 2006 Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. *Hum Pathol* **37**:824–830.
21. Ohori NP, Nikiforova MN, Schoedel KE, LeBeau SO, Hodak SP, Seethala RR, Carty SE, Ogilvie JB, Yip L, Nikiforov YE 2010 Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance.” *Cancer Cytopathol* **118**:17–23.
22. Kim ES, Lim DJ, Lee K, Jung CK, Bae JS, Jung SL, Baek KH, Lee JM, Moon SD, Kang MI, Cha BY, Lee KW, Son HY 2012 Absence of galectin-3 immunostaining in fine-needle aspiration cytology specimens from papillary thyroid carcinoma is associated with favorable pathological indices. *Thyroid* **22**:1244–1250.
23. Jung CK, Im SY, Kang YJ, Lee H, Jung ES, Kang CS, Bae JS, Choi YJ 2012 Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. *Thyroid* **22**:791–797.
24. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN 2009 Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. *J Clin Endocrinol Metab* **94**:2092–2098.
25. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M 2011 Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. *Clin Cancer Res* **17**:4901–4914.
26. VanderLaan PA, Marqusee E, Krane JF 2012 Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for Reporting Thyroid Cytopathology. *Cancer Cytopathol* **120**:245–253.
27. Proietti A, Giannini R, Ugolini C, Miccoli M, Fontanini G, Di Coscio G, Romani R, Berti P, Miccoli P, Basolo F 2010 BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. *Thyroid* **20**:1263–1270.
28. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M 2012 BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. *Medicine* **91**:274–286.
29. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simoes M 2005 Type and prevalence of BRAF mutations are closely associ-

- ated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. *Virchows Archiv* **446**:589–595.
30. Xing M 2005 BRAF mutation in thyroid cancer. *Endocr Relat Cancer* **12**:245–262.
31. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME 2004 Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. *Am J Surg Pathol* **28**:1336–1340.
32. Elsheikh TM, Asa SL, Chan JK, DeLellis RA, Heffess CS, LiVolsi VA, Wenig BM 2008 Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. *Am J Clin Pathol* **130**:736–744.
33. Wallander M, Layfield LJ, Jarboe E, Emerson L, Liu T, Thaker H, Holden J, Tripp S 2010 Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. *Appl Immunohistochem Mol Morphol* **18**:231–235.
34. Nikiforov YE, Nikiforova MN 2011 Molecular genetics and diagnosis of thyroid cancer. *Nat Rev Endocrinol* **7**:569–580.
35. Fernandez-Medarde A, Santos E 2011 Ras in cancer and developmental diseases. *Genes Cancer* **2**:344–358.
36. Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y, Koizume S, Okamoto N, Kondo T, Masuda M, Miyagi Y 2012 The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. *Thyroid* **22**:683–689.

Address correspondence to:

Chan Kwon Jung, MD, PhD

Department of Hospital Pathology

Seoul St. Mary's Hospital

College of Medicine

The Catholic University of Korea

222 Banpodaero, Seocho-gu

Seoul 137-701

Republic of Korea

E-mail: ckjung@catholic.ac.kr